Project/Area Number |
10470265
|
Research Category |
Grant-in-Aid for Scientific Research (B).
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Osaka Medical College |
Principal Investigator |
TANIGAWA Nobuhiko Faculty of Medicine, Osaka Medical College professor, 医学部, 教授 (00111956)
|
Co-Investigator(Kenkyū-buntansha) |
NIKI Masami Faculty of Medicine, Osaka Medical College lecturer, 医学部, 講師 (90271402)
MORITA Shinsyo Faculty of Medicine, Osaka Medical College assistant professor, 医学部, 助教授 (90200419)
|
Project Period (FY) |
1998 – 2000
|
Project Status |
Completed (Fiscal Year 2000)
|
Budget Amount *help |
¥6,400,000 (Direct Cost: ¥6,400,000)
Fiscal Year 2000: ¥1,800,000 (Direct Cost: ¥1,800,000)
Fiscal Year 1999: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 1998: ¥3,200,000 (Direct Cost: ¥3,200,000)
|
Keywords | gene therapy / augmentation of chemosensitivity to anticancer drugs / Fluoro-pyrimidine / Thymidine phosphorylase / PD-ECGF / retroviral vector / digestive cancer / angiogenesis / PD-GCGF / retroviral vcctor |
Research Abstract |
Novel approaches are being investigated for improvement of therapies of human cancers. We have identified a strong association between sensitivity to 5-FU and levels of thymidine phosphorylase (TP) and thymidine kinase (TK) in either human gastric or colon cancer. In addition, after TP/PD-ECGF cDNA was successfully transfected into PC9 cells with use of a plasmid vector, the in vitro mechanism of augmentation of sensitivities to Doxifluridine and 5-FU was partly clarified, by use of the transfected cells, with obtaining confirmatory data of a bystander effect of a type of cell attachment included in the augmentation. A part of our research works, collaborating with the Department of Bacteriology I in Tokyo Jikeikai Medical College, firstly succeeded in yielding a retroviral vector involving TP/PD-ECGF cDNA and we are now conducting the investigation for further clarification of augmentation mechanism of chemosensitivities to Fluoro-pyrimidines. In the mean time, the level of TP enzyme, one of angiogenic peptides, is drastically decreased in both peritoneal seeding cells and in vitro cancer cells. Taken together, it can be considered that this newly developed retroviral vector involving TP/PD-ECGF cDNA may be substantially useful for study of tumor angiogenesis. Thus, the study of a virally directed enzyme prodrug therapy like this would have potential to propose invaluable methods for improvement of cancer chemotherapies.
|